EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Corporate financialization, financing constraints, and innovation efficiency—Empirical evidence based on listed Chinese pharmaceutical companies

Jialin Zhu, Yaning Tang, Yanyi Wei, Su Wang, Yuwen Chen

Frontiers in Public Health · 14.04.2023 · 11

DOI: 10.3389/fpubh.2023.1085148 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Public Health, online erschienen am 14.04.2023. Verfasst von Jialin Zhu und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Business Administration, Shenyang Pharmaceutical University, Shenyang, China. Hauptthemen laut MEDLINE: Drug Industry. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The relationship between financialization and innovation has become a common focus of academic attention. This paper analyzes the influence of corporate financialization on innovation efficiency based on balanced panel data of listed Chinese pharmaceutical companies from 2015 to 2020. Also, it examines the relationship between corporate financialization and innovation efficiency under different levels of financing constraints and the moderating mechanisms that exist. The results of the study show that corporate financialization negatively affects innovation efficiency and that this effect has a lag; corporate financialization hurts innovation efficiency across the different regions and firm nature, with a less inhibiting effect for eastern firms and non-state-owned firms; further tests of the mechanism of action show that there is a non-linear negative relationship between corporate financialization and innovation efficiency. And the inhibition of corporate financialization on innovation efficiency decreases as the level of financing constraints rises. Based on the above findings, this study provides warnings and recommendations for pharmaceutical companies to finance their innovative activities through financialization.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug IndustryChina

Stichwörter der Autor:innen

corporate financializationempirical analysisfinancing constraintsinnovation efficiencylisted pharmaceutical companies

Autor:innen und Institutionen

  • School of Business Administration, Shenyang Pharmaceutical University, Shenyang, China.
  • Drug Regulatory Research Base of NMPA, Research Institute of Drug Regulatory Science, Shenyang Pharmaceutical University, Shenyang, China.

Zitieren

APA

Zhu, J., Tang, Y., Wei, Y., Wang, S., & Chen, Y. (2023). Corporate financialization, financing constraints, and innovation efficiency—Empirical evidence based on listed Chinese pharmaceutical companies. Frontiers in Public Health, 11. https://doi.org/10.3389/fpubh.2023.1085148

Vancouver

Zhu J, Tang Y, Wei Y, Wang S, Chen Y. Corporate financialization, financing constraints, and innovation efficiency—Empirical evidence based on listed Chinese pharmaceutical companies. Frontiers in Public Health. 2023;11. doi:10.3389/fpubh.2023.1085148

BibTeX
@article{Zhu2023,
  author = {Zhu, Jialin and Tang, Yaning and Wei, Yanyi and Wang, Su and Chen, Yuwen},
  title = {Corporate financialization, financing constraints, and innovation efficiency—Empirical evidence based on listed Chinese pharmaceutical companies},
  journal = {Frontiers in Public Health},
  year = {2023},
  volume = {11},
  doi = {10.3389/fpubh.2023.1085148}
}
Kostenlos starten →